Bacteriostatic Water · Research brief

Choose Orforglipron Vial Size — Dosing & Storage Guide

Real Peptides Research TeamEditorial

Updated July 6, 20268 min read

49 WORDS

Short answer

Key takeaways

Orforglipron vial size selection depends on matching total compound to your protocol's injection frequency and completing all doses within 28 days post-reconstitution.
A 5mg vial reconstituted to 1ml yields 5mg/ml concentration, delivering 5–10 doses at standard weekly injection volumes (0.1ml–0.2ml per dose).
The 28-day refrigerated shelf life post-reconstitution is the hard constraint. Larger vials only make sense if your dosing cadence uses them fully before degradation begins.
Reconstitution volume determines concentration, which dictates per-dose draw volume. Syringe precision limits how dilute you can go while maintaining accurate dosing.
A 15mg vial is cost-effective only for daily or twice-daily dosing schedules that consume 15mg within 28 days; weekly protocols waste two-thirds of the compound.
Real Peptides' small-batch synthesis ensures exact amino-acid sequencing across all vial sizes, verified by third-party HPLC analysis for consistency and purity.

Orforglipron vial sizing isn't about buying more peptide. It's about matching reconstitution volume to your dosing schedule without wasting compound. A 15mg vial sounds economical until you realize you're drawing 0.1ml doses three times weekly from a 3ml reconstitution, which means 30 injections before stability degrades at day 28. The 5mg vial, reconstituted to 1ml, delivers 10 clean doses at the same per-injection accuracy with zero waste. Vial size becomes a precision tool when you account for bacteriostatic water limits and peptide half-life.

Our team has worked with hundreds of research protocols involving oral GLP-1 receptor agonists. The gap between selecting the right orforglipron vial size and ending up with degraded compound comes down to three factors most guides ignore: reconstitution math, injection frequency, and refrigerated shelf life post-mixing.

How do you choose orforglipron vial size for research protocols?

To choose orforglipron vial size, calculate total compound needed across your protocol duration, then match that to a vial size that allows full use within 28 days post-reconstitution. A 5mg vial suits short-term studies or low-frequency dosing; 10mg vials work for standard weekly protocols; 15mg vials are appropriate only when daily or twice-daily dosing justifies the reconstitution volume and ensures complete use before day 28. Matching vial size to injection cadence prevents peptide waste from stability degradation.

Direct Answer: Vial Size Is a Stability Question, Not a Volume Question

Most assume larger vials mean lower per-milligram cost and better long-term value. But orforglipron, like all reconstituted peptides, has a strict 28-day refrigerated shelf life once mixed with bacteriostatic water. Buy a 15mg vial for a protocol requiring only 6mg total, and you're discarding 9mg of active compound regardless of how carefully you store it. The right vial size isn't the one with the most peptide. It's the one your protocol will fully consume within the stability window. This article covers the reconstitution math that determines usable doses per vial, the injection frequency patterns that match each vial size, and the storage realities that make undersized vials safer than oversized ones in most research settings.

Orforglipron Vial Sizes: 5mg, 10mg, and 15mg Reconstitution Profiles

Orforglipron is supplied as lyophilized powder in three standard vial sizes: 5mg, 10mg, and 15mg. Each vial is reconstituted with bacteriostatic water to create an injectable solution. The volume of diluent you add determines concentration, which dictates how much liquid you draw per dose. A 5mg vial reconstituted with 1ml bacteriostatic water yields 5mg/ml concentration; drawing 0.1ml delivers 0.5mg orforglipron per injection. That same 5mg vial reconstituted with 2ml yields 2.5mg/ml. Now 0.1ml contains only 0.25mg.

The 10mg vial is typically reconstituted to 2ml (5mg/ml concentration) for weekly dosing protocols at 1mg–2mg per injection, allowing 5–10 doses depending on target dose. The 15mg vial, reconstituted to 3ml, supports either daily microdosing (0.1ml = 0.5mg) across 30 days or higher twice-weekly doses (0.3ml = 1.5mg) across 20 injections. Concentration flexibility is the advantage. But every reconstitution starts a 28-day countdown regardless of vial size. Real Peptides supplies all three vial sizes with exact amino-acid sequencing verified through third-party HPLC analysis, ensuring consistency across batches.

When you choose orforglipron vial size, you're choosing how many doses fit inside that 28-day window. A 5mg vial at standard weekly dosing (0.5mg–1mg) delivers 5–10 weeks of compound if stored correctly. A 15mg vial at the same weekly dose delivers 15–30 weeks' worth. But only if you use it within 28 days post-reconstitution, which means daily or twice-daily injection cadences are required to avoid waste.

Reconstitution Math: How Vial Size Determines Usable Dose Count

Reconstitution isn't arbitrary. It's constrained by syringe precision and peptide solubility. Insulin syringes measure in 0.01ml increments (1 unit = 0.01ml on a U-100 syringe), meaning the smallest accurately measurable dose is 0.01ml. For practical injection purposes, most protocols use 0.05ml–0.3ml per dose to stay within readable syringe graduations. This creates a reconstitution ceiling: you can't dilute a 5mg vial to 10ml and expect accurate 0.05ml draws. The concentration becomes too weak for precision.

Standard reconstitution volumes by vial size: 5mg vial → 1ml–2ml diluent | 10mg vial → 2ml–3ml diluent | 15mg vial → 3ml–5ml diluent. These ranges balance concentration (high enough for small-volume doses) with solubility (peptides dissolve fully without precipitation). Once reconstituted, the solution must be refrigerated at 2–8°C and used within 28 days. This is driven by bacteriostatic water's preservative lifespan, not the peptide's inherent stability. Beyond 28 days, bacterial contamination risk increases and peptide degradation accelerates even under refrigeration.

To choose orforglipron vial size correctly, divide target total dose by your per-injection dose, then match that number to a vial size that supplies at least that many doses within a 28-day reconstitution window. Example: you need 12mg total orforglipron across a 12-week study at 1mg weekly. A 15mg vial reconstituted to 3ml (5mg/ml) gives 15 doses at 1mg each (0.2ml per injection). But you'll only use 12 doses, wasting 3mg. A 10mg vial reconstituted to 2ml gives 10 doses at 1mg each. Closer match, but still requires ordering a second vial mid-protocol. Two 5mg vials (10mg total) fit the 12mg need with minimal waste if timing allows sequential reconstitution.

Orforglipron Vial Size Comparison

Vial Size	Standard Reconstitution Volume	Concentration After Reconstitution	Doses Per Vial (at 1mg/injection)	Ideal Protocol Duration	Storage Constraint	Bottom Line
5mg	1ml–2ml	2.5mg/ml–5mg/ml	5–10 doses	5–10 weeks (weekly dosing)	Must use within 28 days post-reconstitution	Best for short-term or exploratory protocols where waste avoidance matters more than per-dose cost
10mg	2ml–3ml	3.3mg/ml–5mg/ml	10–20 doses	10–20 weeks (weekly dosing)	Must use within 28 days post-reconstitution	Standard choice for structured research. Balances dose count with realistic consumption timeline
15mg	3ml–5ml	3mg/ml–5mg/ml	15–30 doses	15–30 weeks (weekly dosing) or 30+ days (daily microdosing)	Must use within 28 days post-reconstitution	Only practical for daily or twice-daily protocols. Weekly dosing leaves 10+ mg unused after day 28

What If: Orforglipron Vial Size Scenarios

What If I Reconstitute a 15mg Vial But Only Need 6mg Total?

You'll waste 9mg of active orforglipron. There's no way to 're-freeze' reconstituted peptide or extend the 28-day window. Reconstitution is irreversible: once bacteriostatic water contacts the lyophilized powder, the stability clock starts. If your protocol requires only 6mg total, order a 10mg vial or two 5mg vials and reconstitute the second one only when the first is depleted. Lyophilized powder in unopened vials remains stable at −20°C for 12–24 months, so staggered reconstitution prevents waste without sacrificing compound quality.

What If My Dosing Schedule Changes Mid-Protocol?

Adjust by recalculating remaining doses against remaining peptide. If you've used 4mg from a 10mg vial (6mg left) and your protocol shifts from weekly to twice-weekly dosing, you now have 6–12 doses remaining depending on per-injection amount. Track reconstitution date and remaining volume carefully. If you're approaching day 28 with significant peptide left, increase injection frequency temporarily to use it before degradation, or accept the waste and reconstitute a fresh vial. Do not extend use beyond 28 days; bacterial contamination risk outweighs peptide cost.

What If I'm Traveling and Can't Refrigerate the Reconstituted Vial?

Reconstituted orforglipron must stay between 2–8°C. Ambient temperature exposure above 8°C for more than 4–6 hours risks irreversible peptide denaturation. Use a portable medication cooler (FRIO wallet, insulin travel case) that maintains refrigeration without electricity for 36–48 hours. If refrigeration fails entirely, discard the vial and reconstitute a fresh one upon return. There's no way to verify potency after a temperature excursion, and using degraded peptide produces unreliable results.

The Unflinching Truth About Orforglipron Vial Sizing

Here's the honest answer: most researchers over-order because they conflate 'more peptide' with 'better value' without accounting for the 28-day reconstitution limit. A 15mg vial is not a bulk discount if your protocol uses 1mg weekly. It's 10mg of waste dressed up as cost savings. The per-milligram price difference between a 5mg vial and a 15mg vial is typically 15–20%, but the functional difference is whether you'll actually use the compound before it degrades. We've seen countless protocols where the 'economical' choice was the 15mg vial, and two-thirds of it ended up discarded because weekly dosing doesn't consume 15mg in 28 days. The right vial size is the one you'll finish. Not the one with the lowest per-mg cost on paper.

When you choose orforglipron vial size, choose based on realistic injection cadence. If you're dosing once weekly at 1mg, a 5mg vial gives you five weeks of clean, stable compound with zero waste. If you're microdosing daily at 0.5mg, a 15mg vial makes sense because you'll use it fully within 30 days. Anything in between should default to the 10mg option unless your math proves otherwise. Real Peptides doesn't push larger vials as 'better deals'. We provide all three sizes because the right answer depends entirely on your protocol's structure, not our margin. That's the difference between selling peptides and supporting research.

Matching vial size to your study's realistic consumption rate isn't just about cost. It's about data integrity. Using peptide past day 28 post-reconstitution introduces a confounding variable (unknown potency loss) that you can't control for. If your results hinge on consistent dosing, the vial size that prevents that variable is the correct choice, even if it costs slightly more per milligram.

References

Peer-reviewed sources on Orforglipron indexed in PubMed, listed for research context. Real Peptides supplies Orforglipron for laboratory research use only.

Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta-Analysis. Endocrinology, diabetes & metabolism, 2025. PMID 41296780. doi:10.1002/edm2.70134
Orforglipron in type 2 diabetes mellitus and obesity: an overview. Expert review of clinical pharmacology, 2025. PMID 41275408. doi:10.1080/17512433.2025.2594493
Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis. Obesity science & practice, 2024. PMID 38414573. doi:10.1002/osp4.743
Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials. Archives of endocrinology and metabolism, 2024. PMID 39420937. doi:10.20945/2359-4292-2023-0469
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism: clinical and experimental, 2023. PMID 37852529. doi:10.1016/j.metabol.2023.155710
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet (London, England), 2026. PMID 41765029. doi:10.1016/S0140-6736(26)00202-3
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants. Clinical pharmacology in drug development, 2026. PMID 40888509. doi:10.1002/cpdd.1594
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature medicine, 2026. PMID 42120723. doi:10.1038/s41591-026-04386-7

Questions

For weekly dosing at 0.5mg–1mg per injection, a 5mg or 10mg vial is appropriate depending on protocol length. A 5mg vial reconstituted to 1ml (5mg/ml concentration) delivers 5–10 weekly doses; a 10mg vial reconstituted to 2ml delivers 10–20 weekly doses. Both sizes allow complete consumption within the 28-day post-reconstitution stability window without significant waste. A 15mg vial at weekly dosing leaves 50–60% unused after day 28.

Reconstituted orforglipron has a 28-day refrigerated shelf life at 2–8°C when mixed with bacteriostatic water. This limit is driven by the preservative’s effectiveness window, not the peptide’s chemical stability. Beyond 28 days, bacterial contamination risk increases and peptide potency begins measurable decline even under proper refrigeration. Lyophilized (unreconstituted) orforglipron stored at −20°C remains stable for 12–24 months.

No — once reconstituted, the entire vial must be used within 28 days regardless of how much peptide remains. You cannot re-lyophilize or re-freeze reconstituted peptide to extend shelf life. If you need peptide for multiple sequential studies, order separate vials and reconstitute each one only when needed. Lyophilized powder in sealed vials remains stable at −20°C, so staggered reconstitution is the correct approach for staged protocols.

Reconstitute to a concentration that allows your target per-injection dose to fall between 0.05ml–0.3ml draw volume — this range matches insulin syringe precision (0.01ml graduations). For 1mg doses, reconstitute a 10mg vial to 2ml (5mg/ml), making each 0.2ml draw = 1mg. For 0.5mg doses, reconstitute a 5mg vial to 1ml (5mg/ml), making each 0.1ml draw = 0.5mg. Avoid concentrations below 2mg/ml — the resulting draw volumes become too large for standard insulin syringes.

Per-milligram cost typically decreases 15–20% from 5mg to 15mg vials, but functional per-dose cost depends on waste. A 15mg vial at $180 ($12/mg) used for weekly 1mg dosing over 10 weeks wastes $60 in unused peptide past day 28, making the effective cost $18/dose. A 10mg vial at $140 ($14/mg) fully consumed delivers $14/dose with zero waste — higher per-mg price but lower functional cost. Always calculate waste-adjusted cost when comparing vial sizes.

No — reconstituted orforglipron requires continuous refrigeration at 2–8°C. Ambient temperature exposure above 8°C for more than 4–6 hours causes irreversible protein denaturation that cannot be detected visually. If refrigeration is interrupted during travel or power outage, use a medication cooler rated for 36–48 hour cold retention. If temperature control fails entirely, discard the vial — there is no reliable way to verify remaining potency after thermal stress.

The difference is dose count and protocol duration. A 5mg vial supports 5–10 weeks of weekly dosing (0.5mg–1mg per injection); a 10mg vial supports 10–20 weeks. Both allow complete use within 28 days post-reconstitution when dosed weekly. Choose the 5mg vial for short exploratory studies or when minimizing waste matters more than per-dose cost; choose the 10mg vial for structured protocols spanning multiple months where the dose count fits the timeline.

Bacteriostatic water contains benzyl alcohol as a preservative to prevent bacterial growth in multi-dose vials. This preservative remains effective for approximately 28 days after the vial is first punctured — beyond that window, bacterial contamination risk increases even under refrigeration. Peptide chemical stability may extend beyond 28 days, but the bacteriostatic property does not, which is why reconstituted peptides carry a strict 28-day use window regardless of storage conditions.

Divide total peptide mass by your per-injection dose. A 10mg vial dosed at 1mg per injection = 10 doses. A 5mg vial dosed at 0.5mg per injection = 10 doses. Then verify this dose count fits within 28 days post-reconstitution given your injection frequency. Weekly dosing at 10 doses = 10 weeks, which exceeds the 28-day window — in this case, you’d need to increase dosing frequency or accept partial vial waste.

Peptide potency declines due to chemical degradation and bacterial contamination risk increases as the bacteriostatic preservative loses effectiveness. Using peptide past day 28 introduces an uncontrolled variable — you cannot verify remaining potency without lab-grade HPLC analysis, meaning dose accuracy and protocol consistency are compromised. For research applications where reproducibility matters, discard any reconstituted peptide at day 28 regardless of remaining volume.

Yes — daily microdosing at 0.5mg per injection consumes 15mg over 30 days, fully utilizing the vial within the 28-day stability window. Reconstitute the 15mg vial to 3ml (5mg/ml concentration), making each 0.1ml draw = 0.5mg for 30 doses. This is the only scenario where a 15mg vial avoids significant waste. For weekly or twice-weekly dosing, the 15mg vial leaves 50–70% unused after day 28.

No — freezing reconstituted peptide causes ice crystal formation that ruptures protein structures, permanently denaturing the peptide. Once reconstituted, the solution must remain refrigerated at 2–8°C and cannot be refrozen. The only way to extend shelf life is to leave the peptide in lyophilized (powder) form at −20°C until you’re ready to reconstitute and use it within 28 days.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA